Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 9/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 9/20 | 0.45 |
| ▸ | CTSK | P43235 | 6/20 | 0.45 |
| ▸ | CTSS | P25774 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27586355 | 1.00 | HDAC4 (0.46) | HDAC4HDAC1HDAC6ITGB3ITGA2B | |
| SCHEMBL21571117 | 1.00 | HDAC4 (0.46) | HDAC4HDAC1HDAC6ITGB3ITGA2B | |
| SCHEMBL267944 | 0.96 | CTSK (0.46) | HDAC4HDAC1HDAC6ITGB3ITGA2B | |
| SCHEMBL21994806 | 0.95 | CTSK (0.47) | HDAC4HDAC1HDAC6ITGB3ITGA2B | |
| SCHEMBL21994809 | 0.95 | CTSK (0.47) | HDAC4HDAC1HDAC6ITGB3ITGA2B | |
| SCHEMBL21409067 | 0.91 | CTSK (0.44) | HDAC4HDAC1HDAC6ITGB3ITGA2B | |
| SCHEMBL21409064 | 0.91 | CTSK (0.44) | HDAC4HDAC1HDAC6ITGB3ITGA2B | |
| SCHEMBL20179503 | 0.89 | ITGB3 (0.48) | HDAC4HDAC1HDAC6ITGB3ITGA2B | |
| SCHEMBL28937294 | 0.89 | ITGB3 (0.48) | HDAC4HDAC1HDAC6ITGB3ITGA2B | |
| SCHEMBL31407357 | 0.88 | CTSK (0.43) | HDAC4HDAC1HDAC6ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541375-B1 | FACTOR XIIA INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3541375-B1 | FACTOR XIIA INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20220298138-A1 | ENZYME INHIBITORS | SYGNATURE DISCOVERY LIMITED (GB) | 2022-09-22 | — | — | US | disclosed |
| EP-4017586-A1 | ENZYME INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2022-06-29 | — | — | EP | disclosed |
| CN-114269431-A | Enzyme inhibitors | 卡尔维斯塔制药有限公司 | 2022-04-01 | — | — | CN | disclosed |
| WO-2021032933-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032933-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| US-10875851-B2 | Factor XIIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10875851-B2 | Factor XIIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190352294-A1 | Factor XIIa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-11-21 | — | — | US | disclosed |
| US-20190352294-A1 | Factor XIIa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-11-21 | — | — | US | disclosed |
| EP-3541375-A1 | FACTOR XIIa INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018093695-A1 | FACTOR XIIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018093695-A1 | FACTOR XIIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10875851-B2 | Factor XIIa inhibitors | F11, F13B, SERPINC1 | HDAC4 319/4885HDAC1 449/4885HDAC6 574/4885 |
| US-20220298138-A1 | ENZYME INHIBITORS | SERPINB1, CMA1, MAOB | HDAC4 900/4885HDAC1 67/4885HDAC6 732/4885 |
| US-20190352294-A1 | Factor XIIa Inhibitors | F11, F13B, SERPINC1 | HDAC4 319/4885HDAC1 449/4885HDAC6 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.